Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Cash from Investing Activities (2016 - 2024)

NovaBay Pharmaceuticals (NBY) has disclosed Cash from Investing Activities for 14 consecutive years, with $1.1 million as the latest value for Q4 2024.

  • On a quarterly basis, Cash from Investing Activities rose 35633.33% to $1.1 million in Q4 2024 year-over-year; TTM through Sep 2025 was $1.1 million, a 21420.0% increase, with the full-year FY2024 number at $1.1 million, up 5700.0% from a year prior.
  • Cash from Investing Activities was $1.1 million for Q4 2024 at NovaBay Pharmaceuticals, up from -$2000.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $1.1 million in Q4 2024 to a low of -$12.0 million in Q4 2021.
  • A 5-year average of -$742533.3 and a median of -$8000.0 in 2022 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: plummeted 57047.62% in 2021, then skyrocketed 35633.33% in 2024.
  • NovaBay Pharmaceuticals' Cash from Investing Activities stood at -$21000.0 in 2020, then tumbled by 57047.62% to -$12.0 million in 2021, then soared by 99.33% to -$80000.0 in 2022, then surged by 96.25% to -$3000.0 in 2023, then surged by 35633.33% to $1.1 million in 2024.
  • Per Business Quant, the three most recent readings for NBY's Cash from Investing Activities are $1.1 million (Q4 2024), -$2000.0 (Q1 2024), and -$3000.0 (Q4 2023).